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Bioprospecting and Biopiracy in 
Latin America: The Case of 
Maca in Peru 
Amanda J. Landon 
Abstract: Bioprospecting is a popular venture in Latin America due to 
the regions' high concentration of the world's biodiversity. This 
activity has an impact on the native peoples living in areas with 
potentially profitable plants. They can lose access to traditional plants 
and extraction processes when companies patent indigenous cultivars 
and knowledge. In many cases, they cannot patent their cultivars and 
knowledge before others due to cultural and monetary restrictions. In 
this paper, I examine the legal and cultural context surrounding the 
battle over Lepidium meyenii (maca) in Peru. Pure World, Inc., a 
United States pharmaceutical company, patented the extracts derived 
from the plant. It sells these extracts to treat sexual dysfunction in 
humans and other animals. The pharmaceutical company also 
patented the extraction technique. Indigenous peoples in Peru had 
already known about the extracts, the uses for the plant, and the 
extraction technique for thousands of years. They are suing to overturn 
the patents on maca, not to claim patents on the plant for themselves 
but to return the plant to their cultural domain. They have found a way 
to solve their problem with biopiracy without sacrificing their cultural 
values. 
Introduction 
Latin America is a popular destination for bioprospecting, and 
has produced numerous lucrative plants, including the enola bean and 
the maca plant. Companies that bioprospect do not, however, always 
respect the interests and values of the indigenous peoples from whom 
they gather ethnobotanical information and resources. This article 
discusses biopiracy and bioprospecting in Latin America as they relate 
to law, patents, and indigenous groups, focusing on the legal battle over 
Lepidium meyenii (maca) in Peru. The indigenous peoples in Peru are 
using strict Peruvian patent laws to return an important plant to 
indigenous control without sacrificing their cultural values. 
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An understanding of intellectual property rights and patents as 
they apply to indigenous cultures is important for understanding the 
issues surrounding biopiracy. In the United States, two types of patents 
can apply to plant materials: a utility patent for nonobvious, useful, 
and unique plant materials that requires users to pay royalties, and plant 
variety protection that requires additional uniformity, but requires no 
royalties (Brush 1993). Brush (1993) argues that applying intellectual 
property rights to indigenous knowledge is difficult due to the nature of 
indigenous knowledge and communities. To innovate, indigenous 
communities use communal effort, referred to as collective invention, 
in which members of a society freely share information that is used by 
other members. In this sense, indigenous knowledge is communal or 
public knowledge. In addition, due to trading knowledge between 
groups, it is difficult to define the group or groups that own the 
knowledge. If one indigenous group patents part of its communal 
knowledge and resources, other indigenous groups that also rely on the 
knowledge and resources are left out (Brush 1999). Even if indigenous 
groups could find an equitable way to draw a line between who does 
and who does not own certain parts of indigenous knowledge, patents 
are not always compatible with the community-centered values of 
indigenous groups. If indigenous groups do not patent their plant 
resources, allowing corporations such as pharmaceutical companies to 
patent part or all of an indigenous cultivar legitimizes an act that is 
otherwise culturally reprehensible (Brush 1999). Indigenous groups in 
Peru object to the patents that PureWorld, Inc. has on maca for both 
economic and cultural reasons (see case study). 
Bioprospecting refers to acquiring biological resources that 
represent the property of another group of people without a contract 
that assures compensation for access to that genetic resource. This 
notion assumes that the resource is property in the sense that an 
individual or group of individuals literally owns the resource. Some of 
these resources originated in open exchange systems in which many 
individuals from multiple groups contributed to the cultivar and 
associated knowledge, so no easily distinguished group claims 
ownership (Brush 1999). Bioprospecting, in contrast, requires 
reciprocity. The researcher provides both short-term and long-term 
payments for access to the genetic resources (Brush 1999). 
The Global Exchange, a group that follows the issues facing 
indigenous peoples in Mexico, also brings up the problems associated 
with what they refer to as the "privatization of life" (2001:3). The 
privatization of biological materials is a concern because it can result in 
a monopoly over certain natural resources, prevent indigenous peoples 
from being able to obtain food, water and health care, as well as require 
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indigenous peoples to pay for traditional medicines and foods that used 
to belong to them. In this sense, biopiracy also includes corporate 
restriction on the traditional lives of indigenous peoples by way of 
limiting their access to the natural resources that they have traditionally 
used for various purposes. The effects are twofold: indigenous peoples 
can be denied compensation for their knowledge and be charged to use 
the resources the companies discovered using indigenous knowledge. 
Biodiversity, Indigenous Peoples, and Trade 
The Earth's biodiversity "hot spots" tend to be concentrated in 
the tropics (Kleidon & Mooney 2000). Areas with high biodiversity 
also tend to be in countries with the highest poverty levels, especially 
with regard to those living in rural areas. This correlation holds true in 
Latin America where tropical rainforests entice many pharmaceutical 
companies hoping to make a profit from plant extracts, as well as a 
region with a large poor rural population (Bierer et. al 2006). The 
companies wishing to gain access to economically useful plants and 
animals must, then, look to biodiverse countries and the people who 
have experience with the plants to maximize their success in 
bioprospecting ventures. The North American Free Trade Agreement 
(NAFTA), the Rio Convention on Biological Diversity, and the 
Marrakech Agreement are international agreements that affect 
bioprospecting and trade in Latin America. 
NAFT A removed trade barriers between Mexico, the United 
States, and Canada (United States Trade Representative 1993). In 
summary, the agreement reduces or eliminates tariffs on NAFTA 
goods, defines goods covered by NAFT A and sets up guidelines for 
how much of said products must be made out of materials from 
NAFT A countries. The majority of the document consists of lists of 
these items and under which category each falls, as well as definitions 
of items. Annex VII deals with these definitions in relation to Mexico. 
Pharmaceutical products, including some raw materials from which the 
pharmaceuticals are extracted, are covered in the agreement. This 
means that medicinal plants that were found in Mexico and are being 
used by pharmaceutical companies in the United States and Canada are 
covered under NAFT A and are not subject to protectionist tariffs 
(United States Trade Representative 1993). 
NAFT A operates at the governmental level, not between the 
individuals making the transaction. While the United States, Canada 
and Mexico receive some compensation for the resources that are taken 
out of their countries, the individuals who originally discovered the 
resources may be left out. As a result of the agreement, pharmaceutical 
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companies use indigenous knowledge to find plant products to patent 
and are not legally required to compensate them. 
Numerous countries, including the United States and Peru, 
signed the second two agreements. The Rio Convention on Biological 
Diversity of 1992, signed by 162 countries, gives states the right to 
sovereign control over their genetic resources. Each state determines 
who has access to the genetic resources and what sort of compensation 
those granted access must provide in return (Kadidal 1993). The 
Marrakech Agreement, signed by members of the World Trade 
Organization, includes a section that deals with intellectual property 
rights called the Agreement on Trade-Related Aspects of Intellectual 
Property Rights (TRIPS). The agreement allows countries to declare 
that certain objects cannot be patented in order to prevent commercial 
exploitation. These objects include plant and animal life (World Trade 
Organization 1994). These agreements are also between governments, 
not individuals or groups within the countries. Peru passed laws 
regarding patents and biological diversity that protect Peruvian plants 
from patents. These laws are helping indigenous peoples in the country 
protect indigenous plant cultivars. 
Biopiracy, Law, and the Patent System 
Businesses, which usually operate on a utilitarian and legal 
ethical system (meaning ethics are based on that which is legal and is 
considered most useful to themselves and possibly others) see putting 
patents on parts of life forms and derivatives of indigenous knowledge 
as justifiable. Since patents are temporary, the business will not hold a 
monopoly over the plant product forever. Businesses may use 
indigenous knowledge to narrow down which plants to use, but they 
see their role as adding to incomplete, communal knowledge, which is 
seen as public rather than private (Chen 2004). Businesses will patent 
extraction techniques, the chemical reasoning behind the utility of a 
plant and sometimes parts of the plant itself that were uncovered in a 
laboratory. They see processing the plant in the lab as creating 
something new and patentable (Gollin 1999). 
Patents are expensive, although precise cost depends on how 
many claims are made in the patent application, which fees apply to the 
patent, whether the patent is to be national or international, and other 
conditions. The price ranges from hundreds to thousands of dollars 
(United States Patent and Trademark Office 2006). This financial 
barrier alone prevents most indigenous peoples in Latin America from 
patenting their own knowledge, extraction techniques, and cultivars to 
protect against utilization by other groups (Global Exchange 2001). 
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Indigenous cultural values can also prevent these groups from 
obtaining patents. Patents are immoral in some indigenous value 
systems due to the groups' focus on communal rather than private 
ownership (Global Exchange 2001). In this situation, it would be 
difficult for a company to compensate the peoples from which it gained 
information about plants since this exchange could be seen as an 
attempt to buy their knowledge of the plants. This is a problem that 
comes from differences in cultural values, especially those regarding 
ownership. Illegal biopiracy usually deals with what occurs between 
companies and states, leaving out laws to protect the knowledge of 
indigenous peoples. Since indigenous knowledge is communal, it is 
usually viewed as public domain by law. This situation can create 
problems for the indigenous peoples when companies interview them 
for information about plants. There is no way for them to protect their 
knowledge, barring legal action if the company is backed by an entity 
with more power, such as the Peruvian government in the case of the 
maca patents (see case study). 
Indigenous peoples are not only left open to offense from the 
patent system. They can also lose their ability to sell their own plants, 
as was the case with the enola bean in Mexico. POD-NERS, a United 
States seed company, patented the bean and later sued Mexican 
companies that were selling the bean in the United States (Global 
Exchange 2001). The patent system can also lead to indigenous 
cultivars being patented by companies that neither cultivated nor 
greatly altered the plant (Gept 2004). Indigenous peoples have been 
prevented from replanting and selling their own seeds as a result of the 
patent system. 
Legally, there are grave consequences for companies that 
break the law in regard to biopiracy. According to attorney Michael A. 
Gollin (1999), companies that violate biopiracy laws can: have their 
patents revoked, lose the profits that they gained from the illegal patent, 
be prohibited from collecting future samples, and face jail time. 
Legally defined, biopiracy refers to failing to obtain permission to 
collect samples, failing to disclose one's motivations in collecting 
samples, failing to follow national laws, or failing to follow the 
company's self-regulatory guidelines. Left out are widespread laws 
protecting indigenous peoples' intellectual and material property rights. 
Patent laws do not cover indigenous communal knowledge 
since it is seen as old, public domain knowledge. Private knowledge is 
covered, but such knowledge must be new and based on a discovery or 
innovation. Since indigenous peoples do not have the finances to 
patent the plants themselves, companies are generally free to do so 
when they find something commercially useful. They can also patent 
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extraction techniques and applications of the plant or parts of the plant 
since they have the money to do so. It is the immoral rather than the 
illegal biopiracy with which organizations such as Global Exchange, a 
group that tracks instances and effects of biopiracy in Mexico, are 
concerned. 
Some companies and countries are, however, taking steps to 
make bioprospecting a more equitable venture. Shaman 
Pharmaceuticals acknowledges the contribution of indigenous 
knowledge to the company's bioprospecting success. The 
pharmaceutical company claims that 75% of their pharmaceutical 
products were found thanks to the help of indigenous peoples (Bierer et 
al. 2006). Shaman Pharmaceuticals believes that it has found a way to 
fairly compensate the indigenous peoples with whom they work. The 
company argues that, since years can pass before one even knows 
whether or not a new drug will make a profit, both immediate and long 
term forms of compensation are necessary. In the short term, they have 
assisted communities with their health needs by setting up clinics. In 
the long term, they plan to give part of their profits to the communities 
and countries from which they have acquired plants (Bierer et al. 2006). 
Some countries, such as Costa Rica, have found a way to 
arrange for some of the money from bioprospecting ventures go to the 
indigenous peoples who live in the areas where the searches have 
occurred. According to Costa Rica's Biodiversity Law, indigenous 
knowledge is included in the definition of Costa Rican biodiversity (La 
Asamblea Legislativa de la Republica de Costa Rica 1998). Prior 
informed consent must be given before the initiation of any 
bioprospecting venture to all involved, including the indigenous 
peoples of the area. Companies wishing to go bioprospecting must 
purchase a permit in addition to allocating 10% of their research budget 
and as much as 50% of bonuses to the Costa Rican government for the 
National System of Conservation Areas or the indigenous peoples 
and/or private owners on whose property the specimens were found. 
The companies may be required to pay additional money to the 
government in the future to compensate for anything they gain by using 
Costa Rica's biodiversity (La Asamblea Legislativa de la Republica de 
Costa Rica 1998). 
Merck, INBio, and the Costa Rican government reached a deal 
that fulfills this law. Merck pays INBio money to collect samples in 
Costa Rica. Merck then pays royalties to INBio for money it makes 
from developing the samples into drugs. Fifty percent of the royalties 
gained by INBio go to the Costa Rican government for projects related 
to biodiversity and conservation (Coughlin 1993). 
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Maca in Peru, a Case Study 
Indigenous peoples are not without options. La lniciativa 
para fa Prevencion de fa Biopirateria en Peru, a Peruvian legal group, 
is aiding the indigenous peoples there, mostly Quechua and Aymani 
speaking peoples, to revoke the patents held on one of their traditional 
medicinal and food plants, maca (Lepidium meyenii) (Comision 
Nacional contra la Biopirateria 2005). The following case study 
explores the Peruvian legal setting and maca patents, as well as the 
reactions of the Peruvian government and indigenous peoples. The 
indigenous peoples of Peru are using Peruvian law to their advantage in 
order to overturn the patents and to avoid having to define who owns 
maca. 
Peru's General Environmental Law (No. 28611) establishes 
the rules and regulations related to the biodiversity of the country, as 
well as the responsibilities of citizens in relation to the law. One part of 
this law specifically provides for the rights of indigenous peoples and 
traditional communities with regard to their cultures, knowledge, and 
ways of life (Legislative Branch of the Republic of Peru 2005). 
There are currently four main patents held on parts of the 
maca plant by PureWorld, Inc. In one US patent, PureWorld, Inc. 
claims the right to the cellulose-free version of the same extract used by 
indigenous peoples in the Andes. They also claim the extraction 
technique. Indigenous use of the plant is mentioned briefly in the 
description section of the patent (Zheng et al. 2001). In another US 
patent, the company claims more maca extracts, the way in which these 
extracts are used to treat sexual dysfunction in animals (including 
humans), and how the drug is administered to animals (Zheng et al. 
2002). The company claims several more extracts and the methods 
with which to obtain the extracts in a third patent (Zheng et al. 2003). 
In the final patent, the company patents claims rights to several more 
extracts used as treatments for different forms of cancer. This 
particular patent includes a comparatively extensive section of 
background information about common indigenous uses of the maca 
plant, including use as a highly nutritional food source and effective 
medicine (Cui et al. 2005). 
The government of Peru recognizes that patents are important 
tools for businesses in their quest for discoveries, innovations, and 
profits. The Delegation of Peru (2003) at the Geneva Convention 
expressed its views that biopiracy should be dealt with in political 
rather than legal terms since the law generally addresses companies, the 
government, and individuals rather than communities such as the 
indigenous communities. According to Peruvian law, patents cannot be 
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held on parts of plants, including extracts, since neither invention nor 
creative action is involved. Patents including extracts of biological 
origin, such as maca extracts, or including indigenous knowledge, are 
not recognized in Peru (Legislative Branch of the Republic of Peru). 
In the same paper, the Delegation of Peru (2003) 
acknowledges that maca is a plant that has been cultivated over 
thousands of years by the indigenous people of Peru. They cite 
historical references as far back as the 1500s to show that the plant was 
known outside of the indigenous community, as well, for a long time. 
They also cite examples that show that the indigenous peoples and 
traditional communities that have been using maca for generations and 
have known about at least some of the components of the root that the 
company has patented. The rest of the components were previously 
described in a bachelor's thesis by a student at a Peru university 
(Roldan 1961, Delegation of Peru 2003). In the patents, the company 
acknowledges that indigenous peoples had prior knowledge of the 
plant's medicinal use in helping animals with sexual dysfunction. In 
the government of Peru's view, PureWorld, Inc. has discovered nothing 
and should not hold patents over maca. 
The indigenous peoples of Peru now face a problem relating to 
the demand for maca worldwide, which requires so much of the plant 
to be exported. In addition, PureWorld, Inc. has patented an extraction 
technique that is very close to that employed by the indigenous peoples 
using the plant; the only difference is the final step in which the 
company removes the cellulose from the extract (ETC Group 2002). 
Indigenous peoples are also aware that they knew of the many uses of 
maca before PureWorld, Inc. patented anything related to maca. 
PureWorld, Inc. has not discovered anything that their traditional 
communities did not already know. They hope to revoke the 
PureWorld, Inc. patents rather than demand royalties from the 
company's profits (Trade Environment Database 2006). 
Conclusion 
With the backing of the Peruvian government, the indigenous 
peoples living in the Andes are fighting to revoke PureWorld, Inc.'s 
patent rights, at least in Peru if not in the United States. The 
indigenous groups are not going to claim patent ownership on the 
maca. They avoid designating which groups have the right to the plant 
by keeping it in the realm of communal knowledge and cultural 
property. They are not sacrificing their values by claiming individual 
ownership of the plant, either. The indigenous peoples have found a 
solution that is suitable for them in their cultural context. The laws of 
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the two countries involved differ in relation to patents, but without 
Peru's recognition of the US patents held by PureWorld, Inc., the 
indigenous and traditional farmers will be allowed to continue using 
their traditional medicine and selling their extracts outside of the 
United States. 
This case study shows that, in spite of the interests of 
businesses that bioprospect conflicting with indigenous interests, 
indigenous peoples can protect communal knowledge and cultivars on 
indigenous terms. They do not have to bow to national or international 
pressure to either patent their knowledge and cultivars or accept 
royalties from others who patent them. TRIPS and the Convention on 
Biological Diversity give countries the right to sovereign control over 
their plant resources and patents, allowing countries to pass legislation 
that protects indigenous resources. It is vital that indigenous peoples 
have legal recognition, as they do in Peru, to protect their culture from 
exploitation. 
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